Assessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization

Simply Wall St.12-15

LivaNova (LIVN) just brought in Lucile Blaise, a long time ResMed executive, as Global Head of Commercialization for obstructive sleep apnea. The move immediately sharpens the narrative around its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591612557?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-12-15 15:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591612557","market":"nz","top_or_hot":-1,"title":"Assessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization","media":"Simply Wall St.","content":"<div>\n<p>LivaNova (LIVN) just brought in Lucile Blaise, a long time ResMed executive, as Global Head of Commercialization for obstructive sleep apnea. The move immediately sharpens the narrative around its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/assessing-livanova-livns-valuation-after-hiring-resmed-veter\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-15 15:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/assessing-livanova-livns-valuation-after-hiring-resmed-veter><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LivaNova (LIVN) just brought in Lucile Blaise, a long time ResMed executive, as Global Head of Commercialization for obstructive sleep apnea. The move immediately sharpens the narrative around its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/assessing-livanova-livns-valuation-after-hiring-resmed-veter\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B5TLWC47.USD","symbol_name":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/assessing-livanova-livns-valuation-after-hiring-resmed-veter","article_id":"2591612557","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/assessing-livanova-livns-valuation-after-hiring-resmed-veter","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591612557","pubTimestamp":1765783062,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"LivaNova (LIVN) just brought in Lucile Blaise, a long time ResMed executive, as Global Head of Commercialization for obstructive sleep apnea. The move immediately sharpens the narrative around its sleep business.\nSee our latest analysis for LivaNova.\nThe appointment lands as LivaNova enjoys solid momentum, with a roughly 34% year to date share price return and a 25% one year total shareholder return, suggesting investors are warming to its turnaround story.\nIf this leadership move has you...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","LIVN":"LivaNova PLC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4082":"医疗保健设备","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","RMD":"瑞思迈","BK4504":"桥水持仓","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"在聘请瑞思迈资深人士领导睡眠呼吸暂停商业化后评估LivaNova(LIVN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":1.5,"RMD":1.5},"content_text":"LivaNova (LIVN) just brought in Lucile Blaise, a long time ResMed executive, as Global Head of Commercialization for obstructive sleep apnea. The move immediately sharpens the narrative around its sleep business. See our latest analysis for LivaNova. The appointment lands as LivaNova enjoys solid momentum, with a roughly 34% year to date share price return and a 25% one year total shareholder return, suggesting investors are warming to its turnaround story. If this leadership move has you rethinking opportunities in medical devices, it might be worth scanning other promising names in healthcare stocks to see what else matches your conviction. With shares up strongly this year yet still trading below analyst targets and some estimates of intrinsic value, is LivaNova an underappreciated turnaround in sleep and neuromodulation, or has the market already priced in the next leg of growth? Most Popular Narrative: 9.2% Undervalued With LivaNova closing at 62.75 dollars versus a narrative fair value of about 69.10 dollars, the valuation case hinges on steady growth and margin rebuild.  The company's clinical innovations including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability) position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.  Read the complete narrative. Curious how solid device demand, richer margins, and a premium future earnings multiple all intersect to justify that upside gap? The full narrative unpacks every assumption. Result: Fair Value of $69.1 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent healthcare cost pressures and stricter reimbursement review could limit pricing power. At the same time, delayed regulatory milestones might stall adoption and undermine earnings momentum. Find out about the key risks to this LivaNova narrative.  Build Your Own LivaNova Narrative If this take does not quite fit your view, dive into the numbers yourself and shape a custom thesis in minutes with Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding LivaNova. Looking for more investment ideas? Do not stop with one opportunity. Use the Simply Wall St Screener now to line up your next moves before the market races ahead without you.  Capture potential mispricings by targeting these 908 undervalued stocks based on cash flows that pair solid cash flows with room for sentiment to catch up. Tap into structural growth trends through these 30 healthcare AI stocks shaping the future of diagnostics, treatment pathways, and clinical workflows. Pursue asymmetric upside by scanning these 3614 penny stocks with strong financials that already show balance sheet strength and improving fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591612557","isCrawlerRequest":true}